HKMPF News and Press, Hikma Pharmaceuticals Plc From 04/02/20

On Monday,  Amarin (NASDAQ: AMRN) investors got some horrible news. A federal judge in Nevada declared that the company's intellectual property was "obvious" and its drug patent was invalid . This was a complete shock to many investors, including yours truly. Amarin only has one drug, ...

The stock market is currently in a state of turmoil. Due to fears surrounding the rapid spread of the novel coronavirus around the world -- which has now been declared a pandemic by the World Health Organization (WHO) -- the three major U.S. stock market indexes have plunged. Furthermore, thi...

The following slide deck was published by Hikma Pharmaceuticals plc. in conjunction with their 2019 Q4 earnings Read more ...

Amarin (NASDAQ: AMRN) stock climbed 58% last year, and that could be just the beginning. A new indication for its already-marketed drug could be a game changer for the company and its investors. The average analyst price target predicts an upside of 50% from its current price. That and...

With each passing year, I realize that I should concentrate much more on my best ideas, instead of having a few more businesses for the sake of diversification. The specific examples were Facebook ([[FB]]), Apple ([[AAPL]]) and Moody's ([[MCO]]) this year. With Facebook, I decided to not g...

After losing more than 77% of its total enterprise value in less than four years, Akorn, Inc. ( AKRX ) is a name to be followed carefully. The most significant risk is the company’s financial debt, which does not justify the current low valuation. Besides, Akorn recently announced tha...

Hikma Pharmaceuticals PLC (HKMPF) Q2 2019 Earnings Conference Call August 09, 2019 4:30 AM ET Company Participants Siggi Olafsson - Chief Executive Officer Khalid Nabilsi - Chief Financial Officer Conference Call Participants James Vane-Tempest - Jefferies Pete Verdult - Ci...

The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2019 Q2 earnings Read more ...

Acorda Therapeutics ( ACOR ) has had a difficult year with the genericization of their AMPYRA asset coming from a court decision in September 2018. The company has lost over half of its equity value YTD and investors have been continually selling shares even amidst a strong bull market. Howe...

Hikma Pharmaceuticals PLC (HKMPF) Q4 2018 Earnings Conference Call March 13, 2019 05:30 AM ET Company Participants Siggi Olafsson - Chief Executive Officer Khalid Nabilsi - Chief Financial Officer Conference Call Participants James Gordon - JP Morgan Max Hermann - Stifel ...